Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction and Before a Schedule Change

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2024 Jun 24

PMID 38911949

Authors

Lana Childs

Issa Ouedraogo

Robert Lamoussa Zoma

T Felix Tarbangdo

Guetwende Sawadogo

H Flavien Ake

Soumeya Ouangraoua

Soufiane Sanou

Theresa Tran

Srinivasan Velusamy

Tolulope Adebanjo

Chris A Van Beneden

Lesley McGee

Miwako Kobayashi

Affiliations

Soon will be listed here.

Abstract

Background: In October 2013, Burkina Faso introduced 13-valent pneumococcal conjugate vaccine (PCV13) into the routine childhood immunization program using 3 primary doses with no booster. Previous pneumococcal carriage studies showed reductions in vaccine-type (VT) carriage in children aged <5 years but not in older age groups.

Methods: We conducted a cross-sectional, age-stratified pneumococcal carriage study among healthy persons aged ≥1 month in Bobo-Dioulasso in March 2020. Pneumococci isolated by culture from nasopharyngeal swabs (all participants) and oropharyngeal swabs (participants aged ≥5 years) were serotyped by polymerase chain reaction; a subset was serotyped by Quellung. Using data from a study with the same design from March 2017, we examined changes in pneumococcal carriage by age group.

Results: Among 1005 (2017) and 1002 (2020) enrolled participants, VT carriage decreased (21.6% to 15.9%; adjusted prevalence ratio [aPR], 0.76 [95% confidence interval {CI}, .63-.92]). By age group, decline in VT carriage was significant among children aged 5-14 years (28.9% to 16.3%; aPR, 0.57 [95% CI, .39-.84]) but not among children aged <5 years (22.4% to 19.1%; aPR, 0.87 [95% CI, .70-1.09]) or adults aged ≥15 years (12.0% to 5.5%; aPR, 0.52 [95% CI, .26-1.05]).

Conclusions: Between 3 and 6 years after PCV13 introduction, significant declines in VT carriage were observed in older children, possibly reflecting indirect effects of PCV13 use. VT carriage in children aged <5 years remained stable with almost 1 in 5 carrying VT pneumococci, suggesting limitations to a PCV schedule without a booster dose.

References

Spiegelman D, Hertzmark E . Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005; 162(3):199-200. DOI: 10.1093/aje/kwi188. View

. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022; 400(10369):2221-2248. PMC: 9763654. DOI: 10.1016/S0140-6736(22)02185-7. View

Flasche S, van Hoek A, Sheasby E, Waight P, Andrews N, Sheppard C . Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med. 2011; 8(4):e1001017. PMC: 3071372. DOI: 10.1371/journal.pmed.1001017. View

Hammitt L, Bruden D, Butler J, Baggett H, Hurlburt D, Reasonover A . Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis. 2006; 193(11):1487-94. DOI: 10.1086/503805. View

Muller A, Kleynhans J, de Gouveia L, Meiring S, Cohen C, Hathaway L . Streptococcus pneumoniae Serotypes Associated with Death, South Africa, 2012-2018. Emerg Infect Dis. 2021; 28(1):166-179. PMC: 8714227. DOI: 10.3201/eid2801.210956. View

Bosch A, van Houten M, Bruin J, Wijmenga-Monsuur A, Trzcinski K, Bogaert D . Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands. Vaccine. 2015; 34(4):531-539. DOI: 10.1016/j.vaccine.2015.11.060. View

Balsells E, Dagan R, Yildirim I, Gounder P, Steens A, Munoz-Almagro C . The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis. J Infect. 2018; 77(5):368-378. DOI: 10.1016/j.jinf.2018.06.004. View

Usuf E, Bottomley C, Adegbola R, Hall A . Pneumococcal carriage in sub-Saharan Africa--a systematic review. PLoS One. 2014; 9(1):e85001. PMC: 3896352. DOI: 10.1371/journal.pone.0085001. View

Soeters H, Kambire D, Sawadogo G, Ouedraogo-Traore R, Bicaba B, Medah I . Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016-2017. J Infect Dis. 2019; 220(220 Suppl 4):S253-S262. PMC: 8935360. DOI: 10.1093/infdis/jiz301. View

10.

Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling M . Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2016; 5(1):e51-e59. DOI: 10.1016/S2214-109X(16)30306-0. View

11.

van der Linden M, Perniciaro S, Imohl M . Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 2015; 15:207. PMC: 4424534. DOI: 10.1186/s12879-015-0941-9. View

12.

Kabore L, Adebanjo T, Njanpop-Lafourcade B, Ouangraoua S, Tarbangdo F, Meda B . Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys. J Infect Dis. 2021; 224(12 Suppl 2):S258-S266. PMC: 8409529. DOI: 10.1093/infdis/jiab037. View

13.

Nzenze S, von Gottberg A, Shiri T, van Niekerk N, de Gouveia L, Violari A . Temporal Changes in Pneumococcal Colonization in HIV-infected and HIV-uninfected Mother-Child Pairs Following Transitioning From 7-valent to 13-valent Pneumococcal Conjugate Vaccine, Soweto, South Africa. J Infect Dis. 2015; 212(7):1082-92. DOI: 10.1093/infdis/jiv167. View

14.

Conklin L, Loo J, Kirk J, Fleming-Dutra K, Knoll M, Park D . Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J. 2013; 33 Suppl 2:S109-18. PMC: 3944481. DOI: 10.1097/INF.0000000000000078. View

15.

Tiley K, Ratcliffe H, Voysey M, Jefferies K, Sinclair G, Carr M . Nasopharyngeal Carriage of Pneumococcus in Children in England up to 10 Years After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Persistence of Serotypes 3 and 19A and Emergence of 7C. J Infect Dis. 2022; 227(5):610-621. PMC: 9978316. DOI: 10.1093/infdis/jiac376. View

16.

Kwambana-Adams B, Hanson B, Worwui A, Agbla S, Foster-Nyarko E, Ceesay F . Rapid replacement by non-vaccine pneumococcal serotypes may mitigate the impact of the pneumococcal conjugate vaccine on nasopharyngeal bacterial ecology. Sci Rep. 2017; 7(1):8127. PMC: 5557800. DOI: 10.1038/s41598-017-08717-0. View

17.

Mueller J, Yaro S, Ouedraogo M, Levina N, Njanpop-Lafourcade B, Tall H . Pneumococci in the African meningitis belt: meningitis incidence and carriage prevalence in children and adults. PLoS One. 2013; 7(12):e52464. PMC: 3527509. DOI: 10.1371/journal.pone.0052464. View

18.

Valenciano S, Moiane B, Lessa F, Chauque A, Massora S, Pimenta F . Effect of 10-Valent Pneumococcal Conjugate Vaccine on Streptococcus pneumoniae Nasopharyngeal Carriage Among Children Less Than 5 Years Old: 3 Years Post-10-Valent Pneumococcal Conjugate Vaccine Introduction in Mozambique. J Pediatric Infect Dis Soc. 2020; 10(4):448-456. DOI: 10.1093/jpids/piaa132. View

19.

Satzke C, Turner P, Virolainen-Julkunen A, Adrian P, Antonio M, Hare K . Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine. 2013; 32(1):165-79. DOI: 10.1016/j.vaccine.2013.08.062. View

20.

Usuf E, Bottomley C, Gladstone R, Bojang E, Jawneh K, Cox I . Persistent and Emerging Pneumococcal Carriage Serotypes in a Rural Gambian Community After 10 Years of Pneumococcal Conjugate Vaccine Pressure. Clin Infect Dis. 2020; 73(11):e3825-e3835. DOI: 10.1093/cid/ciaa856. View